Cosette Pharmaceuticals Acquires SYMPAZAN and Additional Assets from Assertio Holdings

Cosette Pharmaceuticals has announced the acquisition of SYMPAZAN®, a branded oral film formulation of clobazam, along with additional products from Assertio Holdings, Inc. The transaction marks an expansion of Cosette’s branded pharmaceutical portfolio and includes rights to SYMPAZAN® as well as other undisclosed assets.

SYMPAZAN® is an FDA-approved medication used in the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), a rare and severe form of epilepsy. The product, which utilizes a proprietary oral film technology, provides an alternative for patients who may have difficulty swallowing traditional tablets or capsules. This acquisition aligns with Cosette’s strategy to strengthen its presence in the specialty pharmaceutical market by adding innovative therapies to its offerings. Details regarding the financial terms of the agreement were not disclosed.

The acquisition also includes additional products that were part of Assertio’s portfolio, though specific information about these assets was not provided in the announcement. Cosette Pharmaceuticals stated that this move reflects its commitment to addressing unmet medical needs and expanding access to treatments for patients with complex conditions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI